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Abstract We aimed to systematically evaluate evidence on the
effectiveness of Lactobacillus reuteri DSM 17938 (L. reuteri)
for treating and preventing diseases in infants and children.
MEDLINE and the Cochrane Library were searched in
December 2013, with no language restrictions, for relevant
randomized controlled trials (RCTs) and meta-analyses. The
search was updated in April 2014. One systematic review and
14 RCTs met the inclusion criteria. The use of L. reuterimay be
considered in the management of acute gastroenteritis as an
adjunct to rehydration. There is some evidence that L. reuteri
is effective in reducing the incidence of diarrhea in children
attending day care centers. There is no evidence of effectiveness
of L. reuteri in preventing nosocomial diarrhea in children. The
administration of L. reuteri is likely to reduce crying time in
infants with infantile colic in exclusively or predominantly
exclusively breast-fed infants, but not in formula-fed infants.
More studies are needed. Preliminary data suggest that L. reuteri
may be effective in the prevention of some functional gastroin-
testinal disorders, such as colic and regurgitation. This innova-
tive approach needs further evaluation by an independent re-
search team. Preliminary evidence provides a rationale for fur-
ther assessing the efficacy of L. reuteri for treating functional
constipation or functional abdominal pain. However, it is too
soon to recommend the routine use of L. reuteri for these
conditions. There are no safety concerns with regard to the use
of L. reuteri in nonimmunocompromised subjects. There are
also data to support the safety of using L. reuteri in preterm
infants. Conclusion: Our results precisely define current
evidence on the effects of the administration of L. reuteri
DSM 17938 to the pediatric population.









RCT Randomized controlled trial
RR Relative risk
VAS Visual analog scale
Introduction
Probiotics, defined as live microorganisms, which, when ad-
ministered in adequate amounts, confer a health benefit to the
host [8] are usually discussed jointly. However, all probiotics
are not created equal. Each strain has to be evaluated sepa-
rately for its mechanisms of action, efficacy, and safety.
Lactobacillus reuteri DSM 17938 is the daughter strain of
L. reuteri ATCC 55730. The latter was originally isolated
from the breast milk of a Peruvian mother, and it may be
present in normal humans on the mucosa of the gastric corpus
and antrum, duodenum, and ileum [20, 30]. L. reuteri ATCC
55730 was found to carry potentially transferable resistance
traits for tetracycline and lincomycin. Hence, it was replaced
by L. reuteriDSM 17938, a strain without unwanted plasmid-
borne resistance [23]. It remains a matter of debate whether or
not L. reuteriDSM 17938, the strain with antibiotic resistance
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plasmids removed, and the original L. reuteri ATCC 55730
strain can be regarded as equal. If so, the data on L. reuteri
ATCC 55730 can be extrapolated to L. reuteriDSM 17938. In
principle, these two strains are not identical. However, there
are studies, albeit limited, suggesting the bioequivalence of
both strains. One in vitro study showed similarities with
regard to the chromosomal genes, colony and cell morpholo-
gy, fermentation pattern, mucin binding, and reuterin produc-
tion [30]. Another study documented no differences between
the strains in the characteristics of temporary colonization [6].
On the other hand, at least one study indicated that even the
manufacturing process might influence the properties of pro-
biotic bacteria. In that study, the Finnish group demonstrated
that the differences in the in vitro properties of Lactobacillus
rhamnosus GG isolates, in particular pathogen exclusion by
inhibition and competition, depending on the product source
(matrix) and production processes and conditions [11].
Whether or not these manufacturing differences translate into
differences in vivo, as well as clinical outcomes, is a matter of
discussion. The same uncertainty may apply to the impact of
the removal of the plasmids.
Mechanisms of action of L. reuteri DSM 17938 and/or
L. reuteri ATCC 55730 have been evaluated in a number of
in vitro and animal studies. One of the best-documented
mechanisms is their antimicrobial activity. L. reuteri strains
produce reuterin, a broad-spectrum antibacterial substance [2,
29], which is capable of inhibiting the growth of a wide
spectrum of microorganisms such as Gram-positive or nega-
tive bacteria, yeast, fungi, or parasites [3]. L. reuteri strains
may also regulate immune responses. One such example is the
modulation of TNF-α production from bacterial lipopolysac-
charide (LPS)-activated monocytoid cells in a strain-
dependent manner [15, 16]. With regard to L. reuteri strain
DSM 17938, it was demonstrated that it improved LPS-
induced intestinal morphological damage, including villus
length and density [29]. Moreover, it has been demonstrated
that L. reuteri DSM 17938 significantly reduced intestinal
mucosal levels of KC/GRO (~IL-8) when newborn rats were
fed cow milk formula plus Escherichia coli LPS [17]. More-
over, it has been demonstrated that L. reuteri DSM 17938
reduced intestinal inflammation in an experimental model of
necrotizing enterocolitis via inhibiting a Toll-like receptor-4
signaling pathway that leads to cytokine expression [18].
Finally, some studies have suggested anti-inflammatory prop-
erties of L. reuteri DSM 17938. In vivo studies showed that
this probiotic significantly reduced intestinal mucosal levels
of proinflammatory cytokines (interleukin 8, interleukin-1β,
interferon-γ, tumor necrosis factor alpha) in newborn rats with
LPS-induced small intestinal and ileum inflammation [17].
Taken together, these data show that L. reuteri strains, like
other probiotics, act through diverse mechanisms. These data
also indicate a potential beneficial effect of L. reuteri strains in
treating and preventing diseases in humans.
The aim of this review was to systematically review and
update evidence on the efficacy and safety of using L. reuteri
DSM 17938, regardless of the indication, in infants and chil-
dren. The choice of the probiotic strain was determined by the
facts that it is widely available and it is commonly used in the
pediatric population.
Methods
In December 2013, we searchedMEDLINE and the Cochrane
Library for relevant systematic reviews/meta-analyses of ran-
domized controlled trials (RCTs) and subsequently published
RCTs involving children aged 0 to 18 years. The search was
updated in April 2014. The trials had to compare the use of
L. reuteri DSM 17938 with placebo or no intervention. No
language restriction was imposed. Terms used as a search
strategywere as follows: L. reuteri, DSM 17938, lactobacillus
protectis, child*, infant*, toddler*, adolescent*, and
newborn*. Furthermore, the ClinicalTrials.gov website
(http://clinicaltrials.gov/) and EU Clinical Trials Register
website (https://www.clinicaltrialsregister.eu/) were searched
for trials that were registered but not yet published. All clinical
outcomes reported by the investigators if relevant to the
current review were considered. One reviewer (MU) searched
all databases and undertook data extraction. The risk of bias in
the included studies was assessed using the Cochrane Collab-
oration’s tool for assessing risk of bias. The following criteria
were used: type of randomization method (to assess the risk of
selection bias), allocation concealment (selection bias),
blinding of participants and personnel (performance bias),
blinding of outcome assessment (detection bias), and presence
of intention-to-treat analysis (attrition bias). A low risk of bias
was indicated by an answer of “yes,” and a high risk of bias,
by an answer of “no.”
Results
The literature search yielded one systematic review and 14
RCTs. Table 1 summarizes the characteristics of the included
trials. All included trials were double blinded, except one
single-blinded trial. All were published in English. The ages
of the children enrolled in the trials ranged from birth to
16 years. The daily dose of L. reuteri DSM 17938 ranged
from 1×108 to 4×108 colony-forming units (CFU). With one
exception, all RCTs were placebo controlled; in the remaining
one, there was no additional intervention in the control group.
The studies were undertaken in geographical Europe, the
USA, Australia, and Mexico. Most of the included RCTs
had a low risk of bias (see Table 2 for the methodological
quality of the included trials). A list of excluded trials, mainly
on L. reuteri ATCC 55730, is available upon request. These
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trials were excluded because of questionable bioequivalence
with L. reuteri DSM 17938. Moreover, 17 trials that were
registered, but not published, were identified. These included
therapeutic or preventive studies on infantile colic (four
RCTs), acute gastroenteritis (two RCTs), nosocomial diarrhea
(two RCTs), asthma (one RCT), anorexia (one RCT), gastric
motility in preterm newborns (one RCT), functional abdomi-
nal pain (two RCTs), chronic constipation (one RCT), func-
tional constipation (one RCT), antibiotic-associated diarrhea
(one RCT), and prevention of gastrointestinal and respiratory
tract diseases (one RCT).
Management of acute gastroenteritis
One recent systematic review [28] identified two RCTs [5, 9],
one of which [5] was first published as the abstract only, but is
now published as a full paper. In the first study [9], 74 children
aged 6 to 36 months with acute diarrhea were randomized to
receive L. reuteri DSM 17938 or placebo for 7 days. Com-
pared with the placebo group, in the L. reuteri group, there
was a significant reduction in the duration of diarrhea (3.3±
2.1 vs. 2.1±1.7 days, respectively; P<0.03), the risk of watery
diarrhea on day 2 (81 vs. 55 %, respectively, P<0.02) and day
3 (73 vs. 46 %, respectively, P<0.03), and the risk of relapse
of diarrhea (42 vs. 15%, respectively; P<0.03). There was not
a significant difference in hospital stay between the groups.
The second RCT [5] involved 127 children aged 3−60
months with acute diarrhea who were randomly assigned to
receiveL. reuteriDSM17938 or no intervention, both for 7 days.
In comparison to the control group, the administration of
L. reuteri DSM 17938 significantly reduced the duration of
diarrhea (mean difference (MD) −33.1 h, 95 % confidence
interval (CI) −42.6 to −23.6) and increased the risk of cure on
day 3 (relative risk (RR) 6.2, 95%CI 3.0 to 12.7).Moreover, the
duration of hospitalization was reduced in the L. reuteri group
compared with the control group (4.3±1.3 vs. 5.5±1.8 days,
respectively; P<0.001). Important study limitations include un-
clear adequacy of sequence generation, unclear allocation con-
cealment, single blinding, and lack of intention-to-treat analysis.
The pooled data from these two RCTs showed that compared
with placebo or no treatment, L. reuteriDSM 17938 significant-
ly reduced the duration of diarrhea (MD −32 h, 95 % CI −41 to
−24) and increased the chance of cure on day 3 (RR3.5, 95%CI
1.2 to 10.8, random-effects model) [28]. The authors concluded
that in hospitalized children, the use of L. reuteri DSM 17938
reduced the duration of diarrhea and more children were cured
within 3 days. They also stated that data from outpatients and
country-specific, cost-effectiveness analyses are needed. More-
over, given the limited data and the methodological limitations
of the included trials, the evidence should be viewed with
caution.
In summary, available data document the efficacy of
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developed by the Working Group on Probiotics of the Euro-
pean Society for Paediatric Gastroenterology, Hepatology and
Nutrition, the use of L. reuteriDSM 17938 may be considered
in the management of acute gastroenteritis as an adjunct to
rehydration [27].
Prevention of diarrhea
One RCT [12] assessed the effect of a daily administration of
L. reuteri DSM 17938 for 3 months in preventing diarrhea in
336 otherwise healthy Mexican children aged 6 to 36 months
attending day care centers. Compared with the placebo group,
in the L. reuteri group there was a significant reduction in the
number of episodes of diarrhea, episodes of diarrhea per child,
mean duration of diarrhea episodes, and days with diarrhea
per child both during the intervention and for the next 3-month
follow-up period (the primary outcomes). Moreover, at both 3
and 6 months, there was a significant reduction in the number
of respiratory tract infections (a secondary outcome). A cost-
effectiveness analysis showed that intervention with L. reuteri
DSM 17938 is cost saving for the community.
In conclusion, the findings from this trial suggest that
administering L. reuteri DSM 17938 to children may be
effective in reducing the incidence of diarrhea. These findings
are of importance, as children attending day care centers are at
greater risk for developing gastrointestinal and respiratory
tract infections than children who stay at home. Earlier,
Agustina et al. [1] showed in Indonesian children that the
consumption of regular calcium milk (~440 mg/day) with
L. reuteri DSM 17938 reduced the risk of diarrheal disease,
particularly in malnourished children. Although a direct com-
parison of studies is difficult due the double-intervention in
the study by Agustina et al., the findings from both trials are
encouraging and suggest a means for preventing diarrheal
diseases in children attending day care centers.
Prevention of nosocomial diarrhea
One RCT [31] examined the effect of administering
L. reuteri DSM 17938 for preventing nosocomial diarrhea
in 106 children aged 1 to 48 months. Compared with
placebo, the administration of L. reuteri did not signifi-
cantly affect the risk of developing nosocomial diarrhea,
defined as 3 or more loose or watery stools per 24 h
occurring >72 h from the time of admission to the hospi-
tal (RR 1.06, 95 % CI 0.7 to 1.5) or rotavirus infection
(RR 1.04, 95 % CI 0.6 to 1.6). There was also no
difference between the probiotic and placebo groups for
any of the other secondary outcomes (i.e., incidence of
rotavirus infection, incidence of diarrhea, duration of diar-
rhea, incidence of recurrent diarrhea, incidence of chronic
diarrhea, length of hospital stay in days, and frequency of
need for rehydration).
In conclusion, there is no evidence of effectiveness of
L. reuteri DSM 17938 in preventing nosocomial diarrhea in
children. Further research is needed. One such RCT is cur-
rently underway (NCT01968408).
Management of infantile colic
Three RCTs [24, 25, 26] evaluated the effect of L. reuteri
DSM 17938 for the management of infantile colic. In the first
RCT [24], researchers randomized 50 exclusively breast-fed
infants with infantile colic according to the modified Wessel’s
criteria to receive L. reuteri DSM 17938 or placebo for




(+) indicates a low risk of bias, (−)
indicates a high risk of bias, and















Francavilla et al. [9] (+) (+) (+) (+) (+)
Dinleyici et al. [5] (+) (+) (−) (?) (−)
Gutierrez-Castrellon et al. [12] (+) (+) (+) (?) (+)
Wanke et al. [31] (+) (+) (+) (+) (+)
Savino et al. [24] (+) (−) (+) (+) (+)
Szajewska et al. [26] (+) (+) (+) (+) (+)
Sung et al. [25] (+) (+) (+) (+) (−)
Coccorullo et al. [4] (+) (?) (+) (?) (?)
Romano et al. [22] (+) (+) (+) (+) (?)
Indrio et al. [14] (+) (+) (+) (+) (−)
Indrio et al. (2013) [13] (+) (+) (+) (+) (+)
Garofoli et al. [10] (+) (?) (+) (?) (?)
Rojas et al. [21] (+) (+) (+) (+) (+)
Oncel et al. [19] (+) (+) (+) (+) (+)
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group, the daily crying time was significantly reduced on day
21 [90 min/day (interquartile range 148) vs. 35 min/day
(interquartile range 85), respectively; P=0.022], and there
was a significantly increased number of responders (defined
as 50% reduction in crying time from baseline) on day 7 (8 vs.
20, respectively; P=0.006), day 14 (13 vs. 24, respectively;
P=0.007), and day 21 (15 vs. 24, respectively; P=0.036).
The second RCT [26] involved 80 exclusively or predomi-
nantly (>50 %) breast-fed infants aged <5 months with infantile
colic, also according to the modified Wessel’s criteria. These
infants were randomly assigned to receive L. reuteriDSM17938
or placebo for 21 days. Treatment success, defined as the per-
centage of children achieving a reduction in the daily average
crying time ≥50 %, was significantly higher in the probiotic
group compared with the placebo group at day 7 (P=0.026), at
day 14 (RR 4.3, 95 % CI 2.3 to 8.7), at day 21 (RR 2.7, 95 % CI
1.85 to 4.1), and at day 28 (RR 1.6, 95 % CI 1.3 to 2.1). In
addition, throughout the study period, there was a significant
reduction in the median crying time and in the parental percep-
tion of colic severity for parents of the infants in the probiotic
group compared with the placebo group. Also, visual analog
scale (VAS) scores showed improved parental/family quality of
life throughout the study for parents and families of infants in the
probiotic group compared with the placebo group.
One recent RCT [25] questioned earlier findings. In this trial,
breast- or formula-fed infants (age <3 months) presenting with
infantile colic were randomized to receive daily L. reuteriDSM
17938 or placebo. Of the 167 randomized infants, data from
127 (76 %) were analyzed. At 1 month, the mean daily crying
or fussing time had fallen in both groups. However, compared
with the placebo group, in the probiotic group, the daily crying
time was significantly higher (mean difference 49 min/day,
95 % CI 8 to 90). This was mainly due to more fussing (MD
52min/day, 95%CI 19 to 84), as the crying time was similar in
both groups (MD −2 min/day, 95 % CI −28 to 24). L. reuteri
was not effective in improving infant sleep, maternal mental
health, family or infant functioning, or quality of life.
All three RCTs reported data on crying time on day 21. Here,
we present the pooled results of three RCTs involving 244
infants. Compared with placebo, the administration of L. reuteri
DSM 17938 reduced crying time on day 21 by approximately
43 min (MD −43 min/day, 95 % CI −68 to −19) (Fig. 1). This
was mainly seen in exclusively or predominantly breast-fed
infants (MD −57 min/day, 95 % CI −67 to −46).
In conclusion, the administration of L. reuteri DSM 17938
is likely to reduce crying times in infants with infantile colic,
especially in exclusively or predominantly exclusively breast-
fed infants. More studies, especially in formula-fed infants,
are needed.
Functional constipation
One RCT [4] involved 44 infants aged ≥6 months with func-
tional constipation according to the Rome III criteria who
were randomly assigned to receive L. reuteri DSM 17938 or
placebo for 8 weeks. The primary outcomeswere frequency of
bowel movements per week, stool consistency, and presence
of inconsolable crying episodes. Compared with the placebo
group, infants in the L. reuteri group had a significantly higher
frequency of bowel movements at week 2 (P=0.042), week 4
(P=0.008), andweek 8 (P=0.027). Throughout the study period,
there was no statistically significant difference in stool consisten-
cy or inconsolable crying episodes between the study groups.
In conclusion, this limited data do not allow the routine use
of L. reuteri DSM 17938 in the management of infants with
constipation. Confirmatory studies are needed, particularly
considering the limitations of the study (small sample size,
unclear allocation concealment, unclear blinding of outcome
assessment).
Functional abdominal pain
One double-blind RCT [22] assessed the effect of L. reuteri
DSM 17938 in the treatment of functional abdominal pain
(FAP) according to the Rome III criteria. Sixty children were
randomly assigned to receive either L. reuteri DSM 17938 or
an identical placebo for 4 weeks followed by a 4-week follow-
up period without supplementation. The primary outcomewas
the reduction of the intensity of FAP (Wong-Baker Faces
scale). Compared with the placebo group, in the probiotic
group, FAP intensity decreased significantly at weeks 4 and
8 (week 4: 1.4 vs. 2.0; P<0.001, week 8: 1.2 vs. 2.0; P>0.05).
Fig. 1 Infantile colic. L. reuteri
DSM 17938 compared with
placebo—effect on crying time on
day 21
Eur J Pediatr (2014) 173:1327–1337 1333
There was no difference in FAP symptoms frequency between
the probiotic and the placebo groups.
In conclusion, limited evidence suggests that L. reuteriDSM
17938 may be useful for treating children with FAP. Further
research is needed. One such RCT is currently underway
(NCT01719107).
Regurgitation in infants with gastroesophageal reflux
One double-blind RCT [14] showed that compared with the
administration of placebo (n=15), the administration of
L. reuteri DSM 17938, for 30 days, to 19 formula-fed infants
with regurgitation defined according to the Rome III criteria
(≥2 regurgitations per day for ≥ weeks in otherwise healthy
children) significantly reduced the median number of regur-
gitation episodes per day [4.0 (3.0 to 5.0) vs. 1.0 (1.0 to 2.0),
respectively; P<0.001]. Moreover, compared to the placebo
group, in the probiotic group, the median fasting antral area
was significantly reduced and the delta in the gastric emptying
rate was significantly increased at the end of the intervention
period.
In conclusion, limited available evidence suggests that
L. reuteri DSM 17938 may help in decreasing regurgitation
episodes and improving gastric motility in infants with gas-
troesophageal reflux, but more studies are needed.
Prevention of colic and regurgitation
Two double-blind RCTs studied the prophylactic effect of
L. reuteri DSM 17938 [13, 10].
One small RCT conducted in 40 breast-fed infants who
received L. reuteriDSM 17938 or placebo for the first 28 days
of life found similar durations of crying time, stool frequency,
and stool consistency in both groups. However, compared to
placebo, the administration of L. reuteri DSM 17938 signifi-
cantly reduced the number of daily regurgitation episodes at
the end of the treatment (P=0.02) [10].
In the second, multicenter, large RCT [13], a total of 554
term-born, otherwise healthy breast-fed or formula-fed in-
fants, aged less than 1 week, were randomly assigned to
receive L. reuteri DSM 17938 or placebo for 90 days.
Compared to placebo, the administration of L. reuteri
DSM 17938 resulted in a significant reduction in crying
time at 30 days (96 vs. 45 min/day, respectively; P<0.01)
and at 90 days (71 vs. 38 min/day, respectively, P<0.01).
Moreover, compared to placebo, the administration of
L. reuteri DSM 17938 resulted in a significant reduction
in the number of regurgitation episodes per day, but only on
day 90 (4.6 vs. 2.9, respectively; P<0.01), and a significant
increase in the number of evacuations per day at day 30 (2.8
vs. 4.01, respectively; P<0.01) and at day 90 (3.6 vs. 4.2,
respectively; P<0.01) [13].
In conclusion, for the first time, it was documented in an
RCT that L. reuteri DSM 17938 was effective for preventing
common functional disorders in infants, particularly infantile
colic and regurgitation, in both breast-fed and formula-fed
infants. Replication of these results is needed.
Prevention of necrotizing enterocolitis
Two RCTs were identified that evaluated the effect of
L. reuteri DSM 17938 for preventing necrotizing enteroco-
litis (NEC), nosocomial infections, and sepsis in preterm
infants.
In the first RCT [21], the investigators examined the effects
of administering L. reuteri DSM 17938 compared with place-
bo from the time of enrollment in the first 48 h of life until
death or discharge to 750 preterm infants ≤2,000 g. Overall,
there was no significant difference between the probiotic and
placebo groups in the frequency of death or nosocomial
infection (RR 0.87, 95 % CI 0.63 to 1.19), death (RR 0.8,
95 % CI 0.47 to 1.37), nosocomial infections (RR 0.88, 95 %
CI 0.61 to 1.28), bloodstream infections (RR 1.44, 95 % CI
0.78 to 2.63), positive cultures (RR 0.86, 95 % CI 0.56 to
1.33), nosocomial pneumonia (RR 0.48, 95 % CI 0.22 to
1.05), nosocomial urinary tract infections (RR 2.37, 95 % CI
0.62 to 9.10), nosocomial meningitis (RR 1.02, 95 % CI 0.06
to 16.20), NEC (RR 0.6, 95 % CI 0.27 to 1.38), or episodes of
feeding intolerance (RR 0.7, 95 % CI 0.4 to 1.09). However,
in the subgroup of premature infants ≤1,500 g, there was a
significantly reduced feeding intolerance (P=0.04) and dura-
tion of hospitalization (P=0.03).
In the second RCT [19], researchers randomized 424
preterm infants, with a gestational age of ≤32 weeks and a
birth weight of ≤1,500 g, to receive L. reuteri DSM 17938
or placebo from the time of first feeding until discharge. In
the whole study population, compared to placebo, the ad-
ministration of L. reuteri DSM 17938 had no effect on the
frequency of NEC stage ≥2 (RR 1.26, 95 % CI 0.48 to 3.27)
or the frequency of death or NEC (RR 1.4, 95 % CI 0.76 to
2.59). However, in the probiotic group compared with the
placebo group, there was a significantly reduced risk of
proven sepsis (P=0.041), full feeding day (P=0.006), rate
of feeding intolerance (P=0.015), and duration of hospital
stay (P=0.022).
Here, we present the pooled results of these two RCTs
involving 1,150 preterm infants. Compared with placebo,
the administration of L. reuteriDSM 17938 had no significant
effect on the risk of sepsis, NEC, or death. However, there was
a significant reduction in the risk of feeding intolerance (RR
0.69, 95 % CI 0.54 to 0.88) (Fig. 2).
In conclusion, the use of probiotics for preventing NEC is
one of the most debatable indications for the use of probiotics.
Certain probiotics prevent NEC; however, pooled data failed
to demonstrate that L. reuteri DSM 17938 is one of them.
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Adverse events
L. reuteri DSM 17938 was well tolerated, and no adverse
events associated with its administration were reported in
any of the included trials. Two RCTs [14, 24] assessed
growth parameters and found no difference between the
probiotic and placebo groups. Moreover, in two RCTs
carried out in preterm infants [19, 21], no probiotic grew
from blood cultures.
In conclusion, the use of L. reuteri DSM 17938 in children
with no additional risk factors for adverse events was safe and
well tolerated. Of note, in 2011, the US Food and Drug Admin-
istration (FDA) gave L. reuteriDSM17938, added to term infant
formula, the Generally Regarded as Safe (GRAS) status [7].
Discussion
The objective of this review was to summarize current evidence
on the efficacy and safety of using L. reuteriDSM 17938 in the
pediatric population. The use of L. reuteri DSM 17938 may be
considered in the management of acute gastroenteritis as an
adjunct to rehydration. There is some evidence that L. reuteri
DSM 17938 is effective in reducing the incidence of diarrhea in
children attending day care centers. There is no evidence of
effectiveness of L. reuteriDSM 17938 in preventing nosocomi-
al diarrhea in children. The administration of L. reuteri DSM
17938 is likely to reduce crying times in infants with infantile
colic who are exclusively or predominantly exclusively breast-
fed. More studies in formula-fed infants are needed. Preliminary
data suggest that the administration of L. reuteri DSM 17938
may be effective in the prevention of some functional gastroin-
testinal disorders, such as colic and regurgitation. This innova-
tive approach needs further evaluation by an independent re-
search team. Preliminary evidence provides the rationale for
further assessing the efficacy of L. reuteri DSM 17938 for
treating functional constipation or FAP. However, it is too soon
to recommend the routine use of L. reuteri DSM 17938 in the
management of these conditions. There are no safety concerns
with regard to the use of L. reuteri DSM 17938 in
nonimmunocompromised subjects. There are also data to sup-
port the safety of administering L. reuteri DSM 17938 to
preterm infants; however, the evidence in very low birth weight
infants (<1,000 g) is very limited.
One important strength of our review is that it focused on
one type of a clearly defined, single-organism, probiotic
microorganism, specifically L. reuteri DSM 17938. Thus,
our results precisely define the effects of the administration
of L. reuteri DSM 17938 in the pediatric population. How-
ever, there are also several limitations to this review. One
major issue with any systematic review is the possibility of
publication and other reporting biases. However, with re-
gard to L. reuteri DSM 17938, both positive and negative
RCTs are being published which reduces, although does not
eliminate, the risk of publication bias. Due to the fact that
only single RCTs or a very small number of RCTs were
available, formal assessment of the publication bias was not
feasible. As stated earlier, for some conditions, only single
Fig. 2 The effect of L. reuteri
DSM 17938 compared with
placebo on necrotizing
enterocolitis (NEC), death, sepsis,
and feeding intolerance episode
frequency in preterm infants
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trials were available, and confirmatory studies are, there-
fore, needed. Not only the number of trials but also the
sample sizes in some trials were small. Another limitation is
that the methodological quality of the included trials was
variable.
In conclusion, well-conducted clinical studies using vali-
dated outcome measures are recommended to further identify
populations that would benefit most from L. reuteri DSM
17938 administration. More studies are also needed if the
efficacy of L. reuteri DSM 17938 was proven in a single trial
only. Moreover, studies to evaluate the mechanisms of action
of L. reuteri DSM 17938 are needed.
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